The autoregulatory serglycin/CD44 axis drives stemness-like phenotypes in TNBC in a β-catenin-dependent manner
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Clinical and translational medicine - 11(2021), 2 vom: 03. Feb., Seite e311 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Beta Catenin |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 23.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/ctm2.311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321931432 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321931432 | ||
| 003 | DE-627 | ||
| 005 | 20231225180941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ctm2.311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM321931432 | ||
| 035 | |a (NLM)33634997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Li |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The autoregulatory serglycin/CD44 axis drives stemness-like phenotypes in TNBC in a β-catenin-dependent manner |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 23.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a CD44 protein, human |2 NLM | |
| 650 | 7 | |a Hyaluronan Receptors |2 NLM | |
| 650 | 7 | |a Proteoglycans |2 NLM | |
| 650 | 7 | |a Vesicular Transport Proteins |2 NLM | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 650 | 7 | |a serglycin |2 NLM | |
| 700 | 1 | |a Luo, Fei-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Hong-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Tie-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Li-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Li-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Chao-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Bi-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational medicine |d 2012 |g 11(2021), 2 vom: 03. Feb., Seite e311 |w (DE-627)NLM224642685 |x 2001-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:2 |g day:03 |g month:02 |g pages:e311 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ctm2.311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 2 |b 03 |c 02 |h e311 | ||